Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Novelty in the target landscape of the pharmaceutical industry

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1: Percentage of targets by competitive space.
Figure 2: Competition on novel targets by latest development phase.
Figure 3: Novel targets across the 10 largest pharmaceutical companies.

References

  1. DiMasi, J. A. & Faden, L. B. Competitiveness in follow-on drug R&D: a race or imitation? Nature Rev. Drug Discov. 10, 23–27 (2011).

    CAS  Article  Google Scholar 

  2. Agrawal, V. & Jamwal, S. Top ten global pharma. World Pharmaceutical Frontiers [online], (2011).

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pankaj Agarwal.

Ethics declarations

Competing interests

The authors are all employeees of GlaxoSmithKline.

Related links

FURTHER INFORMATION

Pharmaprojects

PowerPoint slides

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Agarwal, P., Sanseau, P. & Cardon, L. Novelty in the target landscape of the pharmaceutical industry. Nat Rev Drug Discov 12, 575–576 (2013). https://doi.org/10.1038/nrd4089

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4089

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing